"Dr. Steven P. Engebretson, a national and international authority in the areas of periodontology and implant dentistry, has been appointed the new chair of the Ashman Department of Periodontology and Implant Dentistry,” said Dr. Charles Bertolami, Dean, New York University College of Dentistry. “Dr. Engebretson will formally assume his duties on October 1, 2011. He succeeds Dr. Stuart M. Hirsch, who has done an outstanding job as interim chair of the department,” Bretolami said.
“I am delighted to announce that Dr. Steven P. Engebretson, a national and international authority in the areas of periodontology and implant dentistry, has been appointed the new chair of the Ashman Department of Periodontology and Implant Dentistry,” said Dr. Charles Bertolami, Dean, New York University College of Dentistry. “Dr. Engebretson will formally assume his duties on October 1, 2011. He succeeds Dr. Stuart M. Hirsch, who has done an outstanding job as interim chair of the department,” Bretolami said.
Dr. Engebretson comes to NYUCD from the School of Dental Medicine at Stony Brook University, where he has served as associate professor of periodontology and implant dentistry since 2008. An expert in the area of diabetes and oral health, Dr. Engebretson received a $12.5 M grant from the NIH in 2008 for a major diabetes and periodontics clinical trial: The Diabetes and Periodontal Therapy Trial (DPTT). Dr Engebretson will remain the Study Chair and Principal Investigator of this award, which is scheduled to be completed in 2013. He is also the principal investigator on three supplemental awards for the DPTT totaling more than $2.5 M. Dr. Engebretson earned his dental degree at Harvard University after receiving a BA from New York University. He also holds an MS degree in periodontics from Columbia University and an MS degree in biostatistics focusing on patient-oriented research from the Mailman School of Public Health at Columbia University.
Dr. Engebretson is an associate editor of the Journal of Periodontology and maintains a private practice limited to periodontics and implant dentistry. He was awarded a US patent for “Methods for Facilitating Metabolic Control,” and has several additional patents pending. He is the founder of KT Therapeutics, LLC, and OraDelivery, LLC, privately-held biotechnology companies, and is a prolific author and lecturer.
“With his strong academic background and entrepreneurial orientation, Dr. Engebretson brings immense distinction and potential for future achievements to his new post. I hope that you will make him feel especially welcome when he joins us on October 1,” said Bertolami.